Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

NCT01895335 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01895335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01895335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2013
Completion date
November 30, 2015
Enrollment
1,001 (actual)
Sites
169

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis